



The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

23 March 2020

Tekcapital plc
("Tekcapital" or the "Company")
Portfolio Company Update
FDA announced new Guidance to
Expand the Availability of Respiratory Devices

Tekcapital plc, (AIM: TEK) the UK intellectual property investment group focused on creating marketplace value from investing in university technology, notes that the United States Food and Drug Administration (the "FDA") has issued a new policy designed to expand the availability of respiratory devices, including Oxygen Concentrators, during the COVID-19 Pandemic which is potentially relevant to its portfolio company Belluscura plc.

A copy of the FDA announcement may be found [here](#).

About Belluscura plc

Belluscura is focused on developing novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets beyond those traditionally applicable to a single product or product line. Belluscura is developing innovative enriched oxygen treatment platforms that reduce the cost of treatment and increase available treatment options. To learn more about Belluscura, please visit www.belluscura.com.

Tekcapital owns 18.9% of the share capital of Belluscura.

Clifford M. Gross Ph.D., Executive Chairman of Tekcapital plc commented:

"We are very glad to see that the FDA is moving expeditiously to facilitate the supply of respiratory devices during the COVID-19 pandemic."

About Tekcapital plc

Tekcapital creates value from investing in new, university-developed intellectual properties and provides a range of IP investment services to make it easy for organisations to commercialise university-developed technology. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com.

LEI: 213800GOJTOV19FIFZ85

For further information, please contact:

Tekcapital Plc
Clifford M. Gross, Ph.D.

Via Flagstaff

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)
Richard Morrison/Charlie Bouverat (Corporate Finance)

+44 (0) 20 3470 0470

Abigail Wayne (Corporate Broking)

Novum Securities Limited (Joint Broker)

+44 (0) 20 7399 9427

Colin Rowbury (Corporate Broking)

Flagstaff Strategic and Investor Communications

+44 (0) 20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon

This press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving Tekcapital or Belluscura that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of Tekcapital or Belluscura's management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Salarius may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Neither Tekcapital nor Belluscura intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.